First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Tang, Wenlu ^a   Wong, Gavin W K ^a   Perez, Marco I ^a   Wright, James M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALACEPRIL; ALTIOPRIL; ALTIOPRIL CALCIUM; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; CERANAPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; EPROSARTAN; FOSINOPRIL; IMIDAPRIL; IRBESARTAN; LISINOPRIL; MOEXIPRIL; PENTOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; SPIRAPRIL; TEMOCAPRIL; TRANDOLAPRIL; UNINDEXED DRUG; ZOFENOPRIL;

CLINICAL PROTOCOL; CLINICAL RESEARCH; DRUG INFORMATION; DRUG RESEARCH; HUMAN; HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 77950169344     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008170     Document Type: Review

References (24)

1. ABCD-HT 2000 Estacio RO, Jeffers BW, Gifford N, et al.Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2): B54-64.
2. ADA 2005 American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4-36.
3. Aurell 1992 Aurell M, Bjorck S. Determinants of progressive renal disease in diabetes mellitus. Kidney Int Suppl 1992;41(suppl 36):S38-42.
4. CAPPP 2001 Niskanen L, Hedner T, Hansson L, et al.Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on firstline therapy with an ACE inhibitor compared with a diuretic/betablocker- based treatment regimen: a subanalysis of the Captopril Prevention Project (CAPPP). Diabetes Care 2001;24:2091-6.
5. Casas 2005 Casas JP, Chua W, Loukogeorgakis S, et al.Effect of inhibitors of the renin-angiotensin systemand other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366(9502):2026-33.
6. CPG 2008 Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes 2008;32(Suppl 1):S115-8.
7. DeStefano 1993 DeStefano F, Ford ES, Newman J, et al.Risk factors for coronary heart disease mortality among persons with diabetes. Ann Epidemiol 1993;3:27-34.
8. Duprez 2006 Duprez, D. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;24:983-91.
9. Dzau 2001 Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047-52.
10. Geiss 2002 Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S.adults with diabetes, 1988-1994. Am J Prev Med 2002; 22:42-8.
11. HOPE 2000 Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355: 253-9.
12. Inzucchi 2005 Inzucchi S.E, Sherwin R.S. The prevention of type 2 diabetes mellitus. Endocrinol Metab Clin N Am 2005;34(1):199-219.
13. JNC-VII 2003 Chobanian AV, Bakris GL, Black HR, et al.National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
14. Kasiske 1993 Kasiske BL, Kalil RS, Ma JZ, et al.Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta regression analysis. Ann Intern Med 1993;118(2):129-38.
15. Kocks 2002 Kocks MJ, de Zeeuw D, Navis GJ. Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease. Curr Opin Nephrol Hypertens 2002;11:135-40.
16. LIFE 2002 Lindholm LH, Ibsen H, Dahlof B, et al.Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
17. MARVAL 2002 MARVAL Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. Circulation 2002;106:672-8.
18. Pahor 2000 Pahor M, Psaty BM, Alderman MH, et al.Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23:888-92.
19. PROGRESS 2001 PROGRESS Collaborative Study Group. Randomised trial of perindoprilbased blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
20. RENAAL 2001 RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
21. Saha 2008 Saha SA, Molnar J, Arora RR. Tissue angiotensin- converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled metaanalysis of randomized placebo-controlled clinical trials. Diabetes Obesity and Metabolism 2008;10(1):41-52.
22. Siebenhofer 2004 Siebenhofer A, Plank J, Horvath K, et al.Angiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials. Diabetic Medicine 2004;21(1):18-25.
23. Strippoli 2005 Strippoli GFM, Craig ME, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858]
24. Strippoli 2006 Strippoli GFM, Bonifati C, Craig ME, et al.Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858]